Market Overview

Array BioPharma And Others Shine At The ESMO 2017 Congress

Array BioPharma And Others Shine At The ESMO 2017 Congress
Related LLY
Benzinga's Top Upgrades, Downgrades For June 22, 2018
The Market In 5 Minutes: Stress Test Results, More Trade Talks, Viacom's Unexpected Risk
What Does Breakthrough Therapy Designation Really Mean For My Company? (Seeking Alpha)
Related ARRY
The Week Ahead In Biotech: Conferences, Clinical Trials And IPOs
Benzinga's Daily Biotech Pulse: AbbVie Launches New Pediatric Humira, IPO Deluge Hits The Street

The 2017 ESMO Congress wraps up on Tuesday in Madrid, Spain. On Monday, Jefferies issued a handful of flash notes related to companies presenting at the conference.

Here’s a breakdown of the highlights.

Five Prime Therapeutics

Five Prime Therapeutics Inc (NASDAQ: FPRX) reported positive data on its Phase I trials of FP-1039 in treatment of mesothelioma.

“Currently we do not include FP-1039 in our valuation; thus, if successfully developed, it would provide upside,” analyst Eun Yang wrote.

Bristol-Myers Squibb

Analyst Jeffrey Holford said new data on Bristol-Myers Squibb Co (NYSE: BMY)’s CM-214 suggests the market is prematurely writing off Yervoy.

“We see the CM-214 data driving a new indication and growth for Yervoy, helping to support our above consensus 2021E revenue estimate of $3.1bn vs. consensus of $1.8bn,” Holford wrote.

Eli Lilly

Holford said early indications suggest Eli Lilly and Co (NYSE: LLY) breast cancer treatment drug Abema could be the best in its class in terms of efficacy, but more data will be needed to support the initial findings.

“We see room for upside against our own and consensus estimates for Abema and have previously estimated that this could increase mid-term EPS and valuation for LLY by c3%-5%,” he wrote.

Related Link: What Pharmaceuticals Spend On Lobbying To Influence Trump

Array Biopharma

Array Biopharma Inc (NASDAQ: ARRY) reported some positive safety data from its ongoing Phase III BEACON trial. Yang said the new data suggests major potential for Array’s melanoma combination treatment.

“Aside from potential bini/enco approval by ~mid-2018 in somewhat crowded melanoma market, its combo potential in unmet CRC indication with limited competition & ~$1B market size represents likely upside, if successful,” Yang wrote.

Price Targets And Ratings

Jefferies maintains the following ratings and price targets on the four stocks mentioned above:

  • Five Prime—Buy rating, $52 price target
  • Bristol Myers—Buy rating, $66 price target
  • Eli Lilly—Buy rating, $89 price target
  • Array Biopharma—Buy rating, $9 price target

Latest Ratings for LLY

Jun 2018DZ BankDowngradesBuyHold
Jun 2018Credit SuisseMaintainsUnderperformUnderperform
Jun 2018Cantor FitzgeraldInitiates Coverage OnOverweight

View More Analyst Ratings for LLY
View the Latest Analyst Ratings

Posted-In: ESMOAnalyst Color Biotech News Price Target Events Analyst Ratings General Best of Benzinga


Related Articles (ARRY + BMY)

View Comments and Join the Discussion!